聚(ADP-核糖)聚合酶抑制剂耐药机制的研究进展

Research progress of resistance mechanism on PARPi

聚(ADP-核糖)聚合酶抑制剂(PARPi)的发现及临床应用是卵巢恶性肿瘤治疗的重大突破。不仅给同源重组DNA修复缺陷的卵巢癌患者带来福音,而且无同源重组DNA修复缺陷的患者也能从中获益。然而,随着PARPi的临床应用增加,对其产生耐药的风险也明显增加。现系统概述了PARPi耐药的产生机制及其临床应对的可能策略。

The discovery and clinical application of poly(ADP-ribose)polymerase inhibitor(PARPi)is a major breakthrough in the treatment of ovarian malignant tumors.Not only does it bring good news to patients with ovarian cancer who are defective in homologous recombinant DNA repair,but also patients with no defects in homologous recombinant DNA repair can also benefit.However,as the clinical application of PARPi increases,the risk of developing resistance to it is also significantly increased.This review systematically outlines the mechanisms by which PARPi resistance is developed and its possible strategies for clinical response.